Biosimilars Would Have Medicare Parity With Innovators Under Reform Bill
Executive Summary
The potential for physicians to favor innovator biologics over follow-on biologics because of a reimbursement advantage would be eliminated under an amendment to health care reform legislation adopted by the Senate Finance Committee Sept. 23
You may also be interested in...
"Interchangeable" Biosimilars Get Same Medicare Code As Innovators In Bill
Innovator biologics may be in for added pricing pressure from biosimilars under Medicare Part B payment and billing code requirements in the House health reform bill unveiled Oct. 29
"Interchangeable" Biosimilars Get Same Medicare Code As Innovators In Bill
Innovator biologics may be in for added pricing pressure from biosimilars under Medicare Part B payment and billing code requirements in the House health reform bill unveiled Oct. 29
"Interchangeable" Biosimilars Get Same Medicare Code As Innovators In Bill
Reference product payments could decline as proposed payment amounts would be a blend average sales price of the two products.